Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Once-Weekly Semaglutide in Adolescents with Obesity
Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 24, pp. 2245-2257
Open Access | Times Cited: 353

Showing 26-50 of 353 citing articles:

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines
Sten Madsbad, Jens J. Holst
Expert Opinion on Investigational Drugs (2025), pp. 1-19
Open Access | Times Cited: 2
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 37
Association of metabolic syndrome and chronic kidney disease
Florian G. Scurt, Maximilian J. Ganz, Carolin Herzog, et al.
Obesity Reviews (2023) Vol. 25, Iss. 1
Open Access | Times Cited: 37
Current Treatments for Patients with Genetic Obesity
Nathan Faccioli, Christine Poitou, Karine Clément, et al.
Journal of Clinical Research in Pediatric Endocrinology (2023) Vol. 15, Iss. 2, pp. 108-119
Open Access | Times Cited: 34
Semaglutide and cancer: A systematic review and meta-analysis
Lakshmi Nagendra, BG Harish, Meha Sharma, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2023) Vol. 17, Iss. 9, pp. 102834-102834
Closed Access | Times Cited: 34
Pediatric Obesity: Complications and Current Day Management
Mary Ellen Vajravelu, Emir Tas, Silva Arslanian
Life (2023) Vol. 13, Iss. 7, pp. 1591-1591
Open Access | Times Cited: 31
Current and future pharmacotherapies for obesity in children and adolescents
Aaron S. Kelly
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 9, pp. 534-541
Closed Access | Times Cited: 28
Reducing BMI below the obesity threshold in adolescents treated with once‐weekly subcutaneous semaglutide 2.4 mg
Aaron S. Kelly, Silva Arslanian, Dan Hesse, et al.
Obesity (2023) Vol. 31, Iss. 8, pp. 2139-2149
Open Access | Times Cited: 27
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Christine R. Andreasen, Andreas Andersen, Tina Vilsbøll
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1846-1858
Open Access | Times Cited: 27
Obesity in Adolescents
Tamara S. Hannon, Silva Arslanian
New England Journal of Medicine (2023) Vol. 389, Iss. 3, pp. 251-261
Closed Access | Times Cited: 26
The treatment of obesity in children and adolescents: consensus position statement of the Italian society of pediatric endocrinology and diabetology, Italian Society of Pediatrics and Italian Society of Pediatric Surgery
Claudio Maffeis, Francesca Olivieri, Giuliana Valerio, et al.
˜The œItalian Journal of Pediatrics/Italian journal of pediatrics (2023) Vol. 49, Iss. 1
Open Access | Times Cited: 23
Childhood Obesity, Diabetes, and Cardiovascular Disease Risk
Mostafa A. Salama, Babu Balagopal, Ilene Fennoy, et al.
The Journal of Clinical Endocrinology & Metabolism (2023) Vol. 108, Iss. 12, pp. 3051-3066
Closed Access | Times Cited: 22
Potent incretin‐based therapy for obesity: A systematic review and meta‐analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety
Alberte Laura Oest Müllertz, Rasmus Michael Sandsdal, Simon Birk Kjær Jensen, et al.
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 15
Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review
Cătălin Vlăduț Ionuț Feier, Razvan Constantin Vonica, Alaviana Monique Faur, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4346-4346
Open Access | Times Cited: 15
Anti-inflammatory benefits of semaglutide: State of the art
Habib Yaribeygi, Mina Maleki, Tannaz Jamialahmadi, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100340-100340
Open Access | Times Cited: 13
Interventions for Weight Management in Children and Adolescents
Elizabeth O’Connor, Corinne V. Evans, Michelle L. Henninger, et al.
JAMA (2024) Vol. 332, Iss. 3, pp. 233-233
Closed Access | Times Cited: 13
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2024) Vol. 173, pp. 171149-171149
Open Access | Times Cited: 11
Poor Motor Competence Affects Functional Capacities and Healthcare in Children and Adolescents with Obesity
Matteo Vandoni, Luca Marin, Caterina Cavallo, et al.
Sports (2024) Vol. 12, Iss. 2, pp. 44-44
Open Access | Times Cited: 11
New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists
Ferenc Sztanek, László Imre Tóth, Attila Pető, et al.
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1320-1320
Open Access | Times Cited: 11
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis
Hong Li, Guanzheng Yu, Huang Qi, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116150-116150
Open Access | Times Cited: 10
Current and future state of pharmacological management of pediatric obesity
Claudia K. Fox, Aaron S. Kelly, Jessica L. Reilly, et al.
International Journal of Obesity (2024)
Closed Access | Times Cited: 10
Modifiable Cardiometabolic Risk Factors in Survivors of Childhood Cancer
Rawan Hammoud, Daniel A. Mulrooney, Isaac Rhea, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 1, pp. 16-32
Open Access | Times Cited: 8
The Pathophysiological Associations Between Obesity, NAFLD, and Atherosclerotic Cardiovascular Diseases
Meng Li, Man Cui, Guoxia Li, et al.
Hormone and Metabolic Research (2024) Vol. 56, Iss. 10, pp. 683-696
Closed Access | Times Cited: 8
AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys
M. Jensen, Samra Joke Sanni, Ditte Riber, et al.
Molecular Metabolism (2024) Vol. 88, pp. 102006-102006
Open Access | Times Cited: 8
The Rise of Type 2 Diabetes in Children and Adolescents: An Emerging Pandemic
Shiwali Goyal, Vanita Vanita
Diabetes/Metabolism Research and Reviews (2025) Vol. 41, Iss. 1
Closed Access | Times Cited: 1

Scroll to top